444 related articles for article (PubMed ID: 26059702)
1. Rivaroxaban for the treatment and prevention of thromboembolic disease.
Antoniou S
J Pharm Pharmacol; 2015 Aug; 67(8):1119-32. PubMed ID: 26059702
[TBL] [Abstract][Full Text] [Related]
2. Dosing of rivaroxaban by indication: getting the right dose for the patient.
Escolar G; Carne X; Arellano-Rodrigo E
Expert Opin Drug Metab Toxicol; 2015; 11(10):1665-77. PubMed ID: 26329812
[TBL] [Abstract][Full Text] [Related]
3. Practical management of rivaroxaban for the treatment of venous thromboembolism.
Imberti D; Benedetti R
Clin Appl Thromb Hemost; 2015 May; 21(4):309-18. PubMed ID: 24057396
[TBL] [Abstract][Full Text] [Related]
4. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
Cheng JW; Barillari G
J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983
[TBL] [Abstract][Full Text] [Related]
5. The potential role of new oral anticoagulants in the prevention and treatment of thromboembolism.
Mavrakanas T; Bounameaux H
Pharmacol Ther; 2011 Apr; 130(1):46-58. PubMed ID: 21185864
[TBL] [Abstract][Full Text] [Related]
6. Non-vitamin K antagonist oral anticoagulants (NOACs): clinical evidence and therapeutic considerations.
Saraf K; Morris PD; Garg P; Sheridan P; Storey R
Postgrad Med J; 2014 Sep; 90(1067):520-8. PubMed ID: 25085900
[TBL] [Abstract][Full Text] [Related]
7. Rivaroxaban in the treatment of venous thromboembolism and the prevention of recurrences: a practical approach.
Arcelus JI; Domènech P; Fernández-Capitan Mdel C; Guijarro R; Jiménez D; Jiménez S; Lozano FS; Monreal M; Nieto JA; Páramo JA
Clin Appl Thromb Hemost; 2015 May; 21(4):297-308. PubMed ID: 25504999
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor Xa inhibitor.
Kreutz R
Curr Clin Pharmacol; 2014 Feb; 9(1):75-83. PubMed ID: 24218999
[TBL] [Abstract][Full Text] [Related]
9. Rivaroxaban: practical considerations for ensuring safety and efficacy.
Smythe MA; Fanikos J; Gulseth MP; Wittkowsky AK; Spinler SA; Dager WE; Nutescu EA
Pharmacotherapy; 2013 Nov; 33(11):1223-45. PubMed ID: 23712587
[TBL] [Abstract][Full Text] [Related]
10. Rivaroxaban vs. warfarin on extended deep venous thromboembolism treatment: A cost analysis.
Diken AI; Yalçınkaya A; Hanedan MO; Erol ME; Ercen Diken Ö
Phlebology; 2018 Feb; 33(1):53-59. PubMed ID: 28056701
[TBL] [Abstract][Full Text] [Related]
11. A cost-analysis model for anticoagulant treatment in the hospital setting.
Mody SH; Huynh L; Zhuo DY; Tran KN; Lefebvre P; Bookhart B
J Med Econ; 2014 Jul; 17(7):492-8. PubMed ID: 24773068
[TBL] [Abstract][Full Text] [Related]
12. Role of orally available antagonists of factor Xa in the treatment and prevention of thromboembolic disease: focus on rivaroxaban.
Morell J; Sullivan B; Khalabuda M; McBride BF
J Clin Pharmacol; 2010 Sep; 50(9):986-1000. PubMed ID: 20124518
[TBL] [Abstract][Full Text] [Related]
13. Comparing Direct Oral Anticoagulants and Warfarin for Atrial Fibrillation, Venous Thromboembolism, and Mechanical Heart Valves.
Marcy TR; Truong T; Rai A
Consult Pharm; 2015 Nov; 30(11):644-56. PubMed ID: 26629800
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of a Heparin-Calibrated Antifactor Xa Assay for Measuring the Anticoagulant Effect of Oral Direct Xa Inhibitors.
Beyer J; Trujillo T; Fisher S; Ko A; Lind SE; Kiser TH
Clin Appl Thromb Hemost; 2016 Jul; 22(5):423-8. PubMed ID: 26842561
[TBL] [Abstract][Full Text] [Related]
15. Rivaroxaban for the treatment of venous thromboembolism. A "real-life" perspective in 103 patients.
Jara-Palomares L; Sanchez-Oro-Gomez R; Elias-Hernandez T; Morillo-Guerrero R; Ferrer-Galvan M; Asensio-Cruz MI; Barrot-Cortes E; Otero-Candelera R
Thromb Res; 2014 Sep; 134(3):617-21. PubMed ID: 25034320
[TBL] [Abstract][Full Text] [Related]
16. Treatment of patients with acute deep vein thrombosis and/or pulmonary embolism: efficacy and safety of non-VKA oral anticoagulants in selected populations.
Prandoni P
Thromb Res; 2014 Aug; 134(2):227-33. PubMed ID: 24875390
[TBL] [Abstract][Full Text] [Related]
17. Rivaroxaban: a novel, oral, direct factor Xa inhibitor.
Abrams PJ; Emerson CR
Pharmacotherapy; 2009 Feb; 29(2):167-81. PubMed ID: 19170587
[TBL] [Abstract][Full Text] [Related]
18. The current landscape of treatment options for venous thromboembolism: a focus on novel oral anticoagulants.
Hull RD; Gersh MH
Curr Med Res Opin; 2015 Feb; 31(2):197-210. PubMed ID: 25299352
[TBL] [Abstract][Full Text] [Related]
19. Implementing the new oral anticoagulants into the hospital formulary.
Palladino M; Thomson L; Swift B; Merli GJ
Am J Hematol; 2012 May; 87 Suppl 1():S127-32. PubMed ID: 22495943
[TBL] [Abstract][Full Text] [Related]
20. Pharmacodynamic and pharmacokinetic basics of rivaroxaban.
Kreutz R
Fundam Clin Pharmacol; 2012 Feb; 26(1):27-32. PubMed ID: 21848931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
